Jefferies Financial Group’s Arcturus Therapeutics ARCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-24,760
Closed -$781K – 1598
2023
Q4
$781K Buy
+24,760
New +$589K 0.01% 1058
2023
Q2
– Sell
-10,200
Closed -$244K – 1660
2023
Q1
$244K Buy
+10,200
New +$183K ﹤0.01% 1290

Other funds holding ARCT

Jefferies Financial Group's ARCT Position: Q1 2024 in Review

Jefferies Financial Group sold out of Arcturus Therapeutics (ARCT) in Q1 2024, closing a stake of 24,760 shares — an estimated $781K sold.

Jefferies Financial Group first reported a position in ARCT in Q1 2023 and held it in 2 quarters. The position peaked at $781K in Q4 2023. 179 funds tracked by Wall St. Rank hold ARCT as of Q1 2024.

  • Jefferies Financial Group reported no remaining Arcturus Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Jefferies Financial Group sold 24,760 Arcturus Therapeutics shares in Q1 2024, an estimated $781K.
  • Jefferies Financial Group first reported a position in Arcturus Therapeutics in Q1 2023 and held it in 2 quarters.
  • Jefferies Financial Group's Arcturus Therapeutics position peaked at $781K in Q4 2023.
  • 179 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2024.

Based on Jefferies Financial Group's 13F filing for Q1 2024, filed 13 May 2024.